Orient Pharma Co Ltd
Orient Pharma Co Ltd is a pharmaceutical company that develops, produces, and sells generic and branded pharmaceutical products in the healthcare sector.
Business. Orient Pharma Co Ltd (4166.TWO) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in Thailand and is primarily listed on the Thailand Pacific Exchange (TPEx). Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Orient Pharma Co Ltd (4166.TWO) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in Thailand and is primarily listed on the Thailand Pacific Exchange (TPEx). Specific details regarding its operating segments and geographic revenue mix are not available.
Orient Pharma Co Ltd maintains a strong liquidity position, with a current ratio of 6.73, indicating that the company has more than six times the current assets to cover its current liabilities. The company also holds TWD 460 million in cash and equivalents, which provides a buffer against short-term obligations. The debt-to-equity ratio is 0.08, suggesting a conservative capital structure with minimal reliance on debt financing.
In terms of profitability, Orient Pharma Co Ltd reports a return on equity (ROE) of 8.13% and a return on assets (ROA) of 7.09%, both of which are strong indicators of efficient asset utilization and profitability. These metrics are in line with the typical performance of pharmaceutical companies, which often benefit from high gross margins and stable demand for essential medicines.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segmental and geographic detail limits the ability to assess exposure to regional economic or regulatory risks.
Looking ahead, the company's growth trajectory is not explicitly outlined in the available data. However, the operating cash flow of TWD 359.86 million and free cash flow of TWD 294.55 million suggest that the company has the financial flexibility to support future growth initiatives or return capital to shareholders.
The risk assessment indicates that Orient Pharma Co Ltd faces low liquidity and dilution risks. No immediate filing-based liquidity or dilution flags were detected, and the company's capital structure remains stable with low debt levels. The absence of dilution potential and the conservative leverage profile reduce the likelihood of equity dilution in the near term.
There are no recent events or filings disclosed in the available data that would significantly impact the company's operations or financial position. The company appears to be operating in a stable environment with no immediate regulatory or market disruptions.
- Orient Pharma Co Ltd has a strong liquidity position with a current ratio of 6.73 and TWD 460 million in cash and equivalents.
- The company's ROE of 8.13% and ROA of 7.09% indicate efficient asset utilization and profitability.
- The company's capital structure is conservative, with a debt-to-equity ratio of 0.08 and no immediate liquidity or dilution risks.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company has strong operating and free cash flows, which support future growth or shareholder returns.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Orient Pharma Co Ltd Market data — financials · 2026-05-26